Skip to main content

Advertisement

SpringerLink
Log in

Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The HER2 amplicon on chromosome 17q is variable in size and occasionally includes Topoisomerase 2A (TOP2A) at 17q21-22. It has been suggested that TOP2 co-amplification, not HER2 amplification on chromosome 17q11.2-12, is a useful predictive marker of response to anthracycline-based chemotherapy in breast cancer patients. Given the significant toxicities of anthracyclines, the detection methods of TOP2A gene amplifications have to be standardized. We determined TOP2A gene alterations using two different fluorescence in situ hybridization (FISH) DNA probes. HER2 amplifications were identified with the PathVysion™ probe. TOP2A status of 42 HER2 amplified breast cancers was tested by FISH with PathVysion™ covering 160 kb and DAKO pharm DX™ covering 228 kb of the TOP2A amplicon. TOP2A protein expression was tested by immunohistochemistry. Multiplex-ligation dependent probe amplification (MLPA) was performed retrospectively in cases showing discrepancies. TOP2A was amplified in 15 of 42 cases (35%) with DAKO pharm DX™ and in 11 of 42 cases (26%) with PathVysion™. In all four discrepant cases, MLPA showed no TOP2A amplification, but instead amplification of an upstream region including HER2. TOP2A was deleted in the same seven of 42 carcinomas (17%) with both probes. TOP2A protein expression was detected in all 42 tumours (100%) with high intratumoral heterogeneity. TOP2A amplification rate depends on the length of the hybridized probes for the TOP2A locus. Because TOP2A, not HER2, is a target of anthracyclines, non-overlapping DNA probes should be used to evaluate any associations between such alterations and response to anthracycline-based chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS (2007) Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 106:181–189. doi:10.1007/s10549-006-9492-5

    Article  PubMed  CAS  Google Scholar 

  2. Buzdar AU (2006) Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. J Clin Oncol 24:2409–2411. doi:10.1200/JCO.2006.05.9113

    Article  PubMed  Google Scholar 

  3. Coffa J, van de Wiel MA, Diosdado B, Carvalho B, Schouten J, Meijer GA (2008) MLPAnalyzer: data analysis tool for reliable automated normalization of MLPA fragment data. Cell Oncol 30:323–335

    PubMed  CAS  Google Scholar 

  4. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ (2002) HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8:1107–1116

    PubMed  CAS  Google Scholar 

  5. Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, de Vries EG, Rodenhuis S, van de Vijver MJ (2006) Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 95:1334–1341. doi:10.1038/sj.bjc.6603449

    Article  PubMed  CAS  Google Scholar 

  6. Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, Skacel M, Crowe JP, Budd GT, Tubbs RR (2005) The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol 36:348–356. doi:10.1016/j.humpath.2005.01.016

    Article  PubMed  CAS  Google Scholar 

  7. Jacobson KK, Morrison LE, Henderson BT, Blondin BA, Wilber KA, Legator MS, O’Hare A, Van Stedum SC, Proffitt JH, Seelig SA, Coon JS (2004) Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer 40:19–31. doi:10.1002/gcc.20019

    Article  PubMed  CAS  Google Scholar 

  8. Jarvinen TA, Liu ET (2006) Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes—molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 6:579–602

    Article  PubMed  CAS  Google Scholar 

  9. Jarvinen TA, Liu ET (2003) Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer—more common than anticipated. Cytopathology 14:309–313. doi:105[pii]

    Article  PubMed  CAS  Google Scholar 

  10. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J (1999) Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142–150. doi:10.1002/(SICI)1098-2264(199910)26:2<142

    Article  PubMed  CAS  Google Scholar 

  11. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J (2000) Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839–847. doi:S0002-9440(10)64952-8[pii]

    Article  PubMed  CAS  Google Scholar 

  12. Kauraniemi P, Barlund M, Monni O, Kallioniemi A (2001) New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 61:8235–8240

    PubMed  CAS  Google Scholar 

  13. Kauraniemi P, Kallioniemi A (2006) Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 13:39–49. doi:13/1/39[pii]10.1677/erc.1.01147

    Article  PubMed  CAS  Google Scholar 

  14. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdottir K, Olsen KE, Mouridsen H, Ejlertsen B (2005) Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483–7490. doi:10.1200/JCO.2005.11.007

    Article  PubMed  CAS  Google Scholar 

  15. Leo AD, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O’Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 12:1134–1142. doi:10.1016/S1470-2045(11)70231-5

    Article  PubMed  Google Scholar 

  16. Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ (2010) Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 23:1029–1039. doi:10.1038/modpathol.2010.84

    Article  PubMed  CAS  Google Scholar 

  17. Moelans CB, de Weger RA, van Blokland MT, van der Wall E, van Diest PJ (2010) Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod Pathol 23:62–70. doi:10.1038/modpathol.2009.136

    Article  PubMed  CAS  Google Scholar 

  18. Nielsen KV, Muller S, Moller S, Schonau A, Balslev E, Knoop AS, Ejlertsen B (2010) Aberrations of ERBB2 and TOP2A genes in breast cancer. Mol Oncol 4:161–168. doi:10.1016/j.molonc.2009.11.001

    Article  PubMed  CAS  Google Scholar 

  19. O’Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI (2009) Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101:644–650. doi:10.1093/jnci/djp067

    Article  PubMed  Google Scholar 

  20. Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, Nielsen KV, Schonau A, Overgaard J (2004) Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 43:35–42

    Article  PubMed  CAS  Google Scholar 

  21. Park K, Han S, Gwak GH, Kim HJ, Kim J, Kim KM (2006) Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer. Breast Cancer Res Treat 98:337–342. doi:10.1007/s10549-006-9170-7

    Article  PubMed  CAS  Google Scholar 

  22. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ (2011) Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 29:859–867. doi:10.1200/JCO.2009.27.5644

    Article  PubMed  CAS  Google Scholar 

  23. Press MF SG, Buyse L, Bernstein L, Eiermann W, Pienkowski T, Bee V, Taupin H, Seelig S, Slamon DJ (2007) Alteration of topoisomerase II-alpha gene in human breast cancer and its association with responsiveness to anthracycline- based chemotherapy. ASCO 2007 Annual Meeting, Abstract Nr. 524

  24. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, Wilking N, Nilsson J, Bergh J (2006) Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: scandinavian breast group trial 9401. J Clin Oncol 24:2428–2436. doi:10.1200/JCO.2005.02.9264

    Article  PubMed  CAS  Google Scholar 

  25. Tavassoli FA, Devilee P (eds) (2003) World Health Organization classification of tumours: Pathology and Genetics: tumours of the breast and female genital organs. IARC Press, Lyon

    Google Scholar 

  26. Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF (2009) Outcome of patients with early stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 27:3881–3886. doi:10.1200/JCO.2008.20.1566

    Article  PubMed  CAS  Google Scholar 

  27. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145. doi:10.1200/JCO.2006.09.2775

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland

    Zsuzsanna Varga, Ursina Zuerrer-Hardi, Constanze Ramach, Silvia Behnke, Glen Kristiansen & Holger Moch

  2. Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands

    Cathy B. Moelans

Authors
  1. Zsuzsanna Varga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cathy B. Moelans
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ursina Zuerrer-Hardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Constanze Ramach
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Silvia Behnke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Glen Kristiansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Holger Moch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zsuzsanna Varga.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Varga, Z., Moelans, C.B., Zuerrer-Hardi, U. et al. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes. Breast Cancer Res Treat 133, 929–935 (2012). https://doi.org/10.1007/s10549-011-1873-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-011-1873-8

Keywords

Search

Navigation